KALA BIO scraps development of eye disease drug after trial failure
29/09/2025 13:07
Sept 29 (Reuters) - KALA BIO KALA.O said on Monday it will stop developing its experimental treatment for a type of eye disease after it failed to meet the main goal in a mid-stage study. (Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Shreya Biswas) ((Padmanabhan.Ananthan@thomsonreuters.com;))
Recent news on Kalyani Investment
See all newsBrief: Kalyani Investment Recommends Dividend Of 10 Rupees Per Share For FY 2025-26
Brief: Kalyani Investment Appoints Anurag Jain As CEO And CFO
Brief: Kalyani Investment Company Says Shekhar Bhivpathaki Resigns As CEO & CFO
Kala Bio scraps development of eye disease drug after trial failure (updated)
KALA BIO scraps development of eye disease drug after trial failure